AIM: To investigate killer inhibitory and activating receptor expression by natural killer (NK), natural killer T-like (NKT-like) and CD8+ T lymphocytes in patients with chronic hepatitis C virus (HCV) infection with elevated and with persistently normal alanine aminotransferase (PNALT). METHODS: The percentage of peripheral blood Treg cells, KIR2DL3, ILT-2, KIR3DL1, CD160, NKG2D, NKG2C expressing NK, T and NKT-like cells, cytokine production and NK cytotoxicity were determined by flow cytometry. Twenty-one patients with chronic HCV infection with elevated alanine aminotransferase, 11 HCV carriers with persistently normal alanine aminotransferase and 15 healthy volunteers were enrolled. RESULTS: No significant differences were observed in the percentage of total T, NK or NKT-like cells between study groups. Comparing the activating and inhibitory receptor expression by NK cells obtained from HCV carriers with PNALT and chronic HCV hepatitis patients with elevated alanine aminotransferase, NKG2D activating receptor expression was the only receptor showing a significant difference. NKG2D expression of NK cells was significantly lower in patients with elevated alanine aminotransferase. The expression of CD160, NKG2D and NKG2C activating receptor by CD8+ T cells were significantly lower in patients with chronic HCV hepatitis than in healthy controls and in HCV carriers with PNALT. Plasma TGF-β1 levels inversely correlated with NKG2D expression by NK cells. In vitroTGF-β1 treatment inhibited NK cells cytotoxic activity and downregulated NKG2D expression. CD8+ T cells from HCV carriers with PNALT showed significantly elevated expression of CD160, NKG2D and NKG2C activating receptors compared to chronic HCV patients with elevated alanine aminotransferase. Enhanced expression of inhibitory KIR2DL3 receptor, and decreased ILT-2 expression on NK cells were also found in chronic hepatitis C patients compared to healthy controls. CONCLUSION: Our study demonstrated a complex dysregulation of activating and inhibitory receptor expression, such as decreased NKG2D and CD160 activating receptor expression and increased KIR2DL3 inhibitory receptor expression by NK and cytotoxic T cells and may provide further mechanism contributing to defective cellular immune functions in chronic hepatitis C. Increased NKG2D receptor expression in HCV patients with persistently normal ALT suggests an important pathway for sustaining NK and CD8 T cell function and a protective role against disease progression.
AIM: To investigate killer inhibitory and activating receptor expression by natural killer (NK), natural killer T-like (NKT-like) and CD8+ T lymphocytes in patients with chronic hepatitis C virus (HCV) infection with elevated and with persistently normal alanine aminotransferase (PNALT). METHODS: The percentage of peripheral blood Treg cells, KIR2DL3, ILT-2, KIR3DL1, CD160, NKG2D, NKG2C expressing NK, T and NKT-like cells, cytokine production and NK cytotoxicity were determined by flow cytometry. Twenty-one patients with chronic HCV infection with elevated alanine aminotransferase, 11 HCV carriers with persistently normal alanine aminotransferase and 15 healthy volunteers were enrolled. RESULTS: No significant differences were observed in the percentage of total T, NK or NKT-like cells between study groups. Comparing the activating and inhibitory receptor expression by NK cells obtained from HCV carriers with PNALT and chronic HCV hepatitispatients with elevated alanine aminotransferase, NKG2D activating receptor expression was the only receptor showing a significant difference. NKG2D expression of NK cells was significantly lower in patients with elevated alanine aminotransferase. The expression of CD160, NKG2D and NKG2C activating receptor by CD8+ T cells were significantly lower in patients with chronic HCV hepatitis than in healthy controls and in HCV carriers with PNALT. Plasma TGF-β1 levels inversely correlated with NKG2D expression by NK cells. In vitroTGF-β1 treatment inhibited NK cells cytotoxic activity and downregulated NKG2D expression. CD8+ T cells from HCV carriers with PNALT showed significantly elevated expression of CD160, NKG2D and NKG2C activating receptors compared to chronic HCVpatients with elevated alanine aminotransferase. Enhanced expression of inhibitory KIR2DL3 receptor, and decreased ILT-2 expression on NK cells were also found in chronic hepatitis Cpatients compared to healthy controls. CONCLUSION: Our study demonstrated a complex dysregulation of activating and inhibitory receptor expression, such as decreased NKG2D and CD160 activating receptor expression and increased KIR2DL3 inhibitory receptor expression by NK and cytotoxic T cells and may provide further mechanism contributing to defective cellular immune functions in chronic hepatitis C. Increased NKG2D receptor expression in HCVpatients with persistently normal ALT suggests an important pathway for sustaining NK and CD8 T cell function and a protective role against disease progression.
Authors: N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman Journal: J Virol Date: 2001-06 Impact factor: 5.103
Authors: Veronica D Gonzalez; Karolin Falconer; Niklas K Björkström; Kim G Blom; Ola Weiland; Hans-Gustaf Ljunggren; Annette Alaeus; Johan K Sandberg Journal: J Immunol Date: 2009-10-21 Impact factor: 5.422
Authors: Gabriella Pár; Daniel Rukavina; Eckhard R Podack; Margit Horányi; Júlia Szekeres-Barthó; Géza Hegedüs; Mária Paál; László Szereday; Gyula Mózsik; Alajos Pár Journal: J Hepatol Date: 2002-10 Impact factor: 25.083
Authors: David E Kaplan; Kazushi Sugimoto; Kimberly Newton; Mary E Valiga; Fusao Ikeda; Ayse Aytaman; Frederick A Nunes; Michael R Lucey; Barbara A Vance; Robert H Vonderheide; K Rajender Reddy; Jane A McKeating; Kyong-Mi Chang Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: David F G Malone; Sebastian Lunemann; Julia Hengst; Hans-Gustaf Ljunggren; Michael P Manns; Johan K Sandberg; Markus Cornberg; Heiner Wedemeyer; Niklas K Björkström Journal: Front Immunol Date: 2017-05-08 Impact factor: 7.561
Authors: Nadia Marascio; Maria Mazzitelli; Grazia Pavia; Aida Giancotti; Giorgio Settimo Barreca; Chiara Costa; Vincenzo Pisani; Giuseppe Greco; Francesca Serapide; Enrico Maria Trecarichi; Francesco Casalinuovo; Maria Carla Liberto; Giovanni Matera; Carlo Torti Journal: Cells Date: 2019-05-05 Impact factor: 6.600
Authors: Reham Hammad; Mona A Eldosoky; Alshaimaa M Mosaad; Asmaa M El-Nasser; Fatma M Kotb; Salwa I Elshennawy; Noha Abdel-Rahman Eldesoky; Mohamed A Selim; Gina G Naguib; Ossama A Ahmed; Mohamed Alboraie; Reda Badr Aglan Journal: J Hepatocell Carcinoma Date: 2022-07-18